JP2017511350A5 - - Google Patents

Download PDF

Info

Publication number
JP2017511350A5
JP2017511350A5 JP2016562508A JP2016562508A JP2017511350A5 JP 2017511350 A5 JP2017511350 A5 JP 2017511350A5 JP 2016562508 A JP2016562508 A JP 2016562508A JP 2016562508 A JP2016562508 A JP 2016562508A JP 2017511350 A5 JP2017511350 A5 JP 2017511350A5
Authority
JP
Japan
Prior art keywords
sitagliptin
dosage form
tannate complex
oral dosage
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016562508A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017511350A (ja
JP6523328B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/025504 external-priority patent/WO2015160678A1/en
Publication of JP2017511350A publication Critical patent/JP2017511350A/ja
Publication of JP2017511350A5 publication Critical patent/JP2017511350A5/ja
Application granted granted Critical
Publication of JP6523328B2 publication Critical patent/JP6523328B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016562508A 2014-04-17 2015-04-13 タンニン酸シタグリプチン複合体 Active JP6523328B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461980641P 2014-04-17 2014-04-17
US61/980,641 2014-04-17
PCT/US2015/025504 WO2015160678A1 (en) 2014-04-17 2015-04-13 Sitagliptin tannate complex

Publications (3)

Publication Number Publication Date
JP2017511350A JP2017511350A (ja) 2017-04-20
JP2017511350A5 true JP2017511350A5 (enExample) 2017-11-24
JP6523328B2 JP6523328B2 (ja) 2019-05-29

Family

ID=54324454

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016562508A Active JP6523328B2 (ja) 2014-04-17 2015-04-13 タンニン酸シタグリプチン複合体

Country Status (12)

Country Link
US (1) US9833463B2 (enExample)
EP (1) EP3131631B1 (enExample)
JP (1) JP6523328B2 (enExample)
KR (1) KR102351813B1 (enExample)
CN (1) CN106456998B (enExample)
AU (1) AU2015247921B2 (enExample)
BR (1) BR112016023839A8 (enExample)
CA (1) CA2945681A1 (enExample)
ES (1) ES2932383T3 (enExample)
MX (1) MX374598B (enExample)
RU (1) RU2696588C2 (enExample)
WO (1) WO2015160678A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201818969A (zh) * 2016-10-19 2018-06-01 日商帝化製藥股份有限公司 在生體內之藥物溶出控制用組成物
US11096890B2 (en) 2017-09-29 2021-08-24 Merck Sharp & Dohme Corp. Chewable dosage forms containing sitagliptin and metformin
WO2025090920A1 (en) * 2023-10-25 2025-05-01 Piton Therapeutics, Inc. Compositions and methods for treating dysfunction of glucose metabolism and/or regulation

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1856997A (en) 1996-02-02 1997-08-22 Merck & Co., Inc. Method for raising hdl cholesterol levels
US5663415A (en) 1996-06-28 1997-09-02 Jame Fine Chemicals, Inc. Process for preparing antihistamine tannates
AR008789A1 (es) 1996-07-31 2000-02-23 Bayer Corp Piridinas y bifenilos substituidos
WO1999001423A1 (en) 1997-07-01 1999-01-14 Novo Nordisk A/S Glucagon antagonists/inverse agonists
US6613942B1 (en) 1997-07-01 2003-09-02 Novo Nordisk A/S Glucagon antagonists/inverse agonists
WO2000042026A1 (en) 1999-01-15 2000-07-20 Novo Nordisk A/S Non-peptide glp-1 agonists
KR20020014797A (ko) 1999-05-17 2002-02-25 한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느 글루카곤 길항제/역 아고니스트
PE20010612A1 (es) 1999-09-28 2001-07-12 Bayer Corp Agonistas del receptor 3 (r3) del peptido activador de la adenilato ciclasa de la pituitaria y su uso farmacologico
PL395097A1 (pl) 2001-06-11 2011-10-10 Vertex Pharmaceuticals (Canada) Incorporated Sposób wytwarzania związku o wzorze A stanowiącego pochodną tiofenu
UA74912C2 (en) * 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
US20030083354A1 (en) 2001-10-26 2003-05-01 Pediamed Pharmaceuticals, Inc. Phenylephrine tannate and pyrilamine tannate salts in pharmaceutical compositions
US20030114535A1 (en) 2001-12-14 2003-06-19 Jame Fine Chemicals, Inc. Dextrochlorpheniramine tannate
US6670370B1 (en) 2001-12-14 2003-12-30 Jame Fine Chemicals, Inc. Dextromethorphan tannate
JO2625B1 (en) * 2003-06-24 2011-11-01 ميرك شارب اند دوم كوربوريشن Phosphoric acid salts of dipeptidyl betidase inhibitor 4
AU2004268024B2 (en) 2003-09-02 2007-07-12 Merck Sharp & Dohme Llc Novel crystalline forms of a phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
US20070021430A1 (en) 2003-09-23 2007-01-25 Chen Alex M Novel crystalline form of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor
WO2005072530A1 (en) 2004-01-16 2005-08-11 Merck & Co., Inc. Novel crystalline salts of a dipeptidyl peptidase-iv inhibitor
US20050202050A1 (en) * 2004-03-12 2005-09-15 Kiel Jeffrey S. Single tank process for preparing tannate liquid and semi-solid dosage forms
US7612072B2 (en) 2004-09-15 2009-11-03 Merck & Co., Inc. Amorphous form of a phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
US20060270722A1 (en) * 2005-05-31 2006-11-30 Thornberry Nancy A Combination of a dipeptidyl peptidase-IV inhibitor and a dual PPAR agonist for the treatment of diabetes and obesity
EP1909776A2 (en) * 2005-07-25 2008-04-16 Merck & Co., Inc. Dodecylsulfate salt of a dipeptidyl peptidase-iv inhibitor
WO2007050485A2 (en) * 2005-10-25 2007-05-03 Merck & Co., Inc. Combination of a dipeptidyl peptidase-4 inhibitor and an anti-hypertensive agent for the treatment of diabetes and hypertension
WO2008076315A1 (en) * 2006-12-14 2008-06-26 Teva Pharmaceutical Industries, Ltd. Tannate salt of rasagiline
EP2231191A2 (en) * 2007-12-11 2010-09-29 ConjuChem Biotechnologies Inc. Formulation of insulinotropic peptide conjugates
US8003672B2 (en) * 2008-04-21 2011-08-23 Merck Sharp & Dohme Corp. CB-1 receptor modulator formulations
EP2218721A1 (en) * 2009-02-11 2010-08-18 LEK Pharmaceuticals d.d. Novel salts of sitagliptin
US9211263B2 (en) 2012-01-06 2015-12-15 Elcelyx Therapeutics, Inc. Compositions and methods of treating metabolic disorders

Similar Documents

Publication Publication Date Title
RU2560693C2 (ru) Быстро растворяющиеся системы, освобождающие лекарственные препараты
JP2011509295A5 (enExample)
WO2011079239A3 (en) Combination tablet with chewable outer layer
JP2005507400A5 (enExample)
JP2008535867A5 (enExample)
JP2013511507A5 (enExample)
JP2009536147A5 (enExample)
JP2014198723A5 (enExample)
JP2012533565A5 (enExample)
US20110237563A1 (en) Fast dissolving drug delivery systems
JP2016164165A5 (enExample)
FI3710000T3 (fi) Tradipitantti käytettäväksi gastropareesin hoidossa
FI3746126T3 (fi) Menetelmiä ja koostumuksia uniapnean tai pelkän kuorsauksen hoitamiseksi
JP2009501801A5 (enExample)
WO2007119792A1 (ja) 乾式直打速崩壊性錠剤
JP2019218379A5 (enExample)
JP2013536837A5 (enExample)
JP2010511039A5 (enExample)
JP2017511350A5 (enExample)
JP2012505830A5 (enExample)
RU2016144695A (ru) Комплекс танната ситаглиптина
CN101264080A (zh) 一种含有右旋氯苯那敏的药用组合物及其制备方法
CN107582536B (zh) 一种枸橼酸铋钾口腔粘贴片及其制备方法
CN110475547A (zh) 治疗多发性硬化症的组合物和方法
CN110650732A (zh) 锭剂剂型